英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
---|---|---|---|---|---|---|
IOX 2
|
931398-72-0 |
IOX 2
|
N-[[4-羟基-2-氧代-1-(苯基甲基)-1,2-二氢-3-喹啉基]羰基]甘氨酸(IOX-2);2-(1-苄基-4-羟基-2-氧代-1,2-二氢喹啉-3-甲酰氨基)乙酸
|
C19H17N2O4 |
337.34928 | 804-733-4 |
Bafetinib (INNO-406)
|
859212-16-1 |
巴氟替尼
|
NS-187;BAFETINIB;INNO406;巴氟替尼;4-[[(3S)-3-二甲基氨基吡咯烷-1-基]甲基]-N-[4-甲基-3-[(4-嘧啶-5-基嘧啶-2-基)氨基]苯基]-3-(三氟甲基)苯甲酰胺;N-[3-([4,5'-联嘧啶]-2-基氨基)-4-甲基苯基]-4-[[(3S)-3-(二甲基氨基)-1-吡咯烷基]甲基]-3-(三氟甲基)苯甲酰胺
|
C30H31F3N8O |
576.624 | |
CAY10603
|
1045792-66-2 |
CAY10603
|
N-[4-[3-[[[7-(羟基氨基)-7-氧代庚基]氨基]羰基]-5-异恶唑基]苯基]氨基甲酸叔丁酯;CAY10603;CAY-10603;CAY 10603.
|
C22H30N4O6 |
446.4968 | |
GW 5074
|
220904-83-6 |
GW5074
|
(3Z)-3-[(3,5-DIBROMO-4-HYDROXYPHENYL)METHYLIDENE]-5-IODO-1H-INDOL-2-ONE;GW 5074;GW-5074;GW5074;GW-5074;GW 5074;3-(3,5-二溴-4-羟基苯亚甲基)-5-碘-1,3-二氢吲哚-2-酮
|
C15H8Br2INO2 |
520.94 | |
GSK461364
|
929095-18-1 |
GSK461364
|
CS-553;GSK-461364;GSK-461364A;5-[6-[(4-甲基-1-哌嗪)甲基]-1H-苯并咪唑-1-基]-3-[(1R)-1-[2-(三氟甲基)苯基]乙氧基]-2-噻吩羧胺;GSK461364;5-[6-[(4-甲基-1-哌嗪基)甲基]-1H-苯并咪唑-1-基]-3-[(1R)-1-[2-(三氟甲基)苯基]乙氧基]-2-噻吩甲酰胺;GSK461364,一种有效的 POLO-LIKE KINASE 1 抑制剂
|
C27H28F3N5O2S |
543.611 | 200-258-5 |
GSK2606414
|
1337531-36-8 |
GSK2606414
|
GSK2606414;7-甲基-5-[1-[[3-(三氟甲基)苯基]乙酰基]-2,3-二氢-1H-吲哚-5-基]-7H-吡咯并[2,3-D]嘧啶-4-胺;CS-868;GSK2606414;GSK 2606414;GSK-2606414;GSK2606414;GSK-2606414
|
C24H20F3N5O |
451.46 | |
GSK2126458
|
1086062-66-9 |
GSK2126458; GSK-2126458
|
2,4-二氟-n-[2-甲氧基-5-[4-(4-吡嗪)-6-喹啉]-3-吡啶]苯磺酰胺;CS-55;GSK2126458;GSK-2126458;2,4-二氟-N-[2-甲氧基-5-[4-(4-哒嗪基)-6-喹啉基]-3-吡啶基]苯磺酰胺;2,4-二氟-N-[2-甲氧基-5-[4-(4-吡嗪)-6-喹啉]-3-吡啶]苯磺酰胺;HYR-582;GSK2126458 (GSK458);GSK458;GSK-212;GSK-2126458;OMIPALISIB,一种有效的高度选择性PI3K抑制剂
|
C25H17F2N5O3S |
505.4959864 | 629-873-1 |
GNE-7915
|
1351761-44-8 |
GNE7915
|
GNE7915;GNE 7915;CS-1279
|
C19H21F4N5O3 |
443.395353 | |
GNE 317
|
1394076-92-6 |
GNE-317
|
CS-1716;GNE-317;GNE 317;GNE317;GNE-317;5-[6-(3-METHOXYOXETAN-3-YL)-7-METHYL-4-MORPHOLIN-4-YLTHIENO[3,2-D]PYRIMIDIN-2-YL]PYRIMIDIN-2-AMINE
|
C18H20N6O3S |
400.4548 | |
Gisadenafil besylate-UK 369003 | PF 01224715
|
334827-98-4 |
GISADENAFIL BESYLATE
|
|
C23H33N7O5S.C6H6O3S |
678 | |
GDC 0941 bismesylate-Pictilisib
|
957054-33-0 |
GDC0941
|
PICTILISIB DIMETHANESULFONATE;GDC-0941 (2 MESO3H SALT);GDC0941 DIMETHANESULFONATE;GDC-0941;GDC0941;GDC 0941;PICTILISIB DIMETHANESULFONATE;GDC-0941 (2 MESO3H SALT);GDC-0941;2-(1H-吲唑-4-基)-6-[[4-(甲基磺酰基)-1-哌嗪基]甲基]-4-(4-吗啉基)噻吩并[3,2-D]嘧啶二甲磺酸盐
|
C24H30N7O6S3 |
608.7333 | |
FRAX486
|
1232030-35-1 |
FRAX486
|
|
C25H23Cl2FN6O |
513.394123 | |
FR 180204
|
865362-74-9 |
FR180204
|
5-(2-苯基吡唑并[1,5-A]吡啶-3-基)-1H-吡唑并[3,4-C]哒嗪-3-胺;FR 180204,一种ATP-竞争性的选择性的ERK抑制剂
|
C18H13N7 |
327 | |
Forskolin
|
66575-29-9 |
佛司可林
|
福斯高林;佛司可林,来源于毛喉鞘蕊花;福斯高林,毛喉萜,考福新,锦紫苏醇;佛司可林(福斯高林,锦紫苏醇);弗斯可林;毛喉鞘蕊
|
C22H34O7 |
410.5 | 266-410-9 |
FG-2216-YM 311
|
223387-75-5 |
FG-2216-YM 311
|
[[(1-氯-4-羟基异喹啉-3-基)羰基]氨基]乙酸;2-(1-氯-4-羟基异喹啉-3-甲酰氨基)乙酸
|
C12H9ClN2O4 |
280.66386 | |
Fendiline hydrochloride
|
13636-18-5 |
盐酸芬他林
|
盐酸芬他林
|
C23H26ClN |
351.91 | 237-121-5 |
Fatostatin hydrobromide-Fatostatin A hydrobromide | 125B11 hydrobromide
|
298197-04-3 |
FATOSTATIN
|
|
C18H18N2S.HBr |
375.328 | |
EPZ015666
|
1616391-65-1 |
EPZ015666
|
EPZ-015666;EPZ 015666;GSK3235025;EPZ-015666;EPZ 015666;N-[(2S)-3-(3,4-二氢-2(1H)-异喹啉基)-2-羟基丙基]-6-(3-氧杂环丁基氨基)-4-嘧啶甲酰胺
|
C20H25N5O3 |
383.4442 | |
enzastaurin
|
170364-57-5 |
Enzastaurin (LY317615)
|
3-(1-甲基-1H-吲哚-3-基)-4-(1-(1-(2-吡啶甲基)-4-哌啶基)-1H-吲哚-3-基)-1H-吡咯-2,5-二酮;因扎妥雷;恩扎妥林;3-(1-甲基-1H-吲哚-3-基)-4-(1-(1-(吡啶-2-基甲基)哌啶-4-基)-1H-吲哚-3-基)-1H-吡咯-2,5-二酮;恩扎妥林(LY317616);恩扎妥林,一种有效的PKCΒ选择性抑制剂
|
C32H29N5O2 |
515.6 | |
DMOG
|
89464-63-1 |
二甲基乙二酰氨基乙酸
|
DMOG;DIMETHYLOXALLYL GLYCINE;DIMETHYLOXALYLGLYCINE;89464-63-1;METHYL N-[METHOXY(OXO)ACETYL]GLYCINATE;二甲基乙二酰氨基乙酸;METHYL 2-(2-METHOXY-2-OXOETHYLAMINO)-2-OXOACETATE;二甲基草酰甘氨酸;二甲基乙二酰氨基乙酸>98%
|
C6H9NO5 |
175.14 | 200-256-5 |